A Medical Device Daily

Antares Pharma (Ewing, New Jersey) reported it has entered into a fourth agreement with Teva Pharmaceutical Industries (Jerusalem) under which Antares will develop and supply a new disposable pen injector for use with two patient-administered pharmaceuticals.

Teva will purchase all of its requirements for the pen injector from Antares for use with the two undisclosed products. Both products are subject to FDA approval.

Antares will receive an up-front cash payment, milestone fees and an undisclosed percentage of the selling price of the combined pharmaceutical and device product, net of certain costs.

Antares is the manufacturer of record and will also receive the selling price for each injector device from Teva. In addition, Antares retains rights to the new pen injector for use with other pharmaceutical and biological products not covered under the agreement.

Jack Stover, president/CEO of Antares, said, “These potential new products contribute further confidence to our sales ramp up and royalty growth plans with four new product introductions possible between 2008 through 2012. We also now have a strong competitive entry in a new growth segment of the injectable pen market.”

In addition to the new pen injector, Antares’ portfolio of injection devices includes the Vibex mini-needle injectors, and two needle-free injection systems: the Medi-Jector Vision and Medi-Jector Valeo.

In other agreement news:

• Jan Insulet (Bedford, Massachusetts) and DexCom (San Diego) said they have signed a development agreement to integrate DexCom’s continuous glucose monitoring technology into the wireless, hand-held OmniPod System Personal Diabetes Manager (PDM).

In addition to programming the patient’s insulin delivery, the PDM with integrated DexCom technology will receive and display continuous glucose readings from DexCom’s wearable sensor transmitter. Patients using the integrated system will have access to real-time glucose values and trended glucose information, as well as alarms to warn patients if glucose levels are rising or falling.